Journal Article

New treatment for IgA nephropathy: enteric budesonide targeted to the ileocecal region ameliorates proteinuria

Hilde Kloster Smerud, Peter Bárány, Karin Lindström, Anders Fernström, Anna Sandell, Peter Påhlsson and Bengt Fellström

in Nephrology Dialysis Transplantation

Published on behalf of European Renal Association - European Dialysis and Transplant Assoc

Volume 26, issue 10, pages 3237-3242
Published in print October 2011 | ISSN: 0931-0509
Published online March 2011 | e-ISSN: 1460-2385 | DOI:
New treatment for IgA nephropathy: enteric budesonide targeted to the ileocecal region ameliorates proteinuria

Show Summary Details


Background. Systemic corticosteroid treatment has been shown to exert some protection against renal deterioration in IgA nephropathy (IgAN) but is not commonly recommended for long-term use due to the well-known systemic side effects. In this study, we investigated the efficacy and safety of a new enteric formulation of the locally acting glucocorticoid budesonide (Nefecon®), designed to release the active compound in the ileocecal region. The primary objective was to evaluate the efficacy of targeted release budesonide on albuminuria.

Methods. Budesonide 8 mg/day was given to 16 patients with IgAN for 6 months, followed by a 3-month follow-up period. The efficacy was measured as change in 24-h urine albumin excretion, serum creatinine and estimated glomerular filtration rate (eGFR).

Results. The median relative reduction in urinary albumin excretion was 23% during the treatment period (interquartile range: −0.36 to −0.04, P = 0.04) with pretreatment values ranging from 0.3 to 6 g/24 h (median: 1.5 g/24 h). The median reduction in urine albumin peaked at 40% (interquartile range: −0.58 to −0.15) 2 months after treatment discontinuation. Serum creatinine was reduced by 6% (interquartile range: −0.12 to −0.02; P = 0.003), and eGFR [Modification of Diet in Renal Disease (MDRD)] increased ∼8% (interquartile range: 0.02–0.16, P = 0.003) during treatment. No major corticosteroid-related side effects were observed.

Conclusions. In the present pilot study, enteric budesonide targeted to the ileocecal region had a significant effect on urine albumin excretion, accompanied by a minor reduction of serum creatinine and a modest increase of eGFR calculated by the MDRD equation, while eGFR calculated from Cockcroft–Gault equation and cystatin C was not changed. Enteric budesonide may represent a new treatment of IgAN warranting further investigation.

Keywords: budesonide; clinical trial; corticosteroid; IgA nephropathy; prospective

Journal Article.  3959 words.  Illustrated.

Subjects: Nephrology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.